PhRMA blasts FDA plans to post preliminary info on side effects

PhRMA is fighting the FDA's plans to post preliminary information about the potentially harmful side effects of drugs, saying that the early warning system is likely to lead to "irrational fears" and confusion among consumers. The FDA has proposed launching a "Drug Watch" page on its website, listing the safety concerns it had under investigation. PhRMA President Billy Tauzin says that bad data on the site could prompt patients to stop taking medications that they need.

- read this story from Pharmaceutical News for more

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.